
Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and the importance of evidence-based guidelines.

Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and the importance of evidence-based guidelines.


A groundbreaking biologics license application for ivonescimab targets advanced lung cancer, promising improved outcomes for patients with EGFR mutations.

The FDA denies accelerated approval for tabelecleucel, highlighting ongoing challenges in treating EBV-positive posttransplant lymphoproliferative disease.

During a live event, Joshua K. Sabari, MD, discussed subgroup analyses and safety outcomes of the IMforte trial in extensive-stage small cell lung cancer.

A novel oral fascin inhibitor, NP-G2-044, shows promise in treating pancreatic cancer, earning FDA orphan drug designation for innovative therapies.

New trial data highlight zanidatamab's potential to enhance survival in HER2-positive gastroesophageal adenocarcinoma, challenging existing treatment standards.


A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival (PFS) in patients with metastatic colorectal cancer.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment options for challenging patient populations.

Discover the latest breakthroughs in oncology, including FDA approvals, innovative treatments, and promising trial results shaping cancer care today.

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

FDA meeting guides Plus Therapeutics in advancing rhenium Re 186 obisbemeda for leptomeningeal metastases, paving the way for pivotal trials.

A retrospective study of patients treated with an alternate dose schedule of ipilimumab plus nivolumab in advanced melanoma found improvements in both tolerability and efficacy.

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid limited options.

A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.

The FDA designates zoldonrasib as a breakthrough therapy for KRAS G12D-mutated lung cancer, highlighting its promising efficacy and safety profile.

The FDA clears KLN-1010, a groundbreaking in vivo gene therapy for relapsed multiple myeloma, enhancing CAR-T treatment accessibility and efficacy.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

CPI-008 receives orphan drug designation, enhancing surgical imaging for pancreatic cancer and promising improved outcomes in challenging surgeries.

Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies.

A new trial explores the effectiveness of calderasib combined with pembrolizumab for advanced lung cancer patients with the KRAS G12C mutation.

During a live event, Jan Drappatz, MD, and participants discussed which patients with glioma should receive IDH inhibitors and what next steps could identify who will benefit.

A recent study reveals CAR T-cell therapy patients in Europe experience quality of life comparable to the general population, yet face ongoing physical and mental challenges.

Promising interim results highlight the potential of Olvi-Vec in treating advanced lung cancer, showcasing efficacy and safety in challenging patient populations.

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options.

A recent analysis highlights the efficacy of melphalan/HDS for metastatic uveal melanoma, showing improved outcomes in patients with lower hepatic tumor burden.

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed their approaches to TKI dose modification and immune checkpoint inhibitor rechallenge in advanced renal cell carcinoma.

A new drug application for rusfertide aims to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient outcomes.